Pharmaceutical Executive October 10, 2024
Off-the-shelf cell therapies hold immense promise for revolutionizing precision medicine by offering accessible and affordable treatments. However, overcoming the immune system’s rejection and navigating the FDA’s approval process are crucial challenges.
Cell therapy is advancing to a future where treatments are ready-made and accessible, bypassing the limitations of current personalized medicine. In recent years, cell therapy has evolved from autologous (using one’s own cells) to allogeneic (using cells from donors), also known as off-the-shelf therapies.
The biggest challenge with off-the-shelf cell therapies is the risk of the immune system rejecting them entirely. Because we don’t fully understand how the chain reactions — akin to dominos falling in a network — in the immune system work, we are at a crossroads.
...Today's Sponsors
Today's Sponsor